Drug Type CAR-NK, Induced pluripotent stem cells (iPSC) |
Synonyms GD2-iNK(Seoul National University Hospital), TB 302, TB302 |
Target |
Action inhibitors |
Mechanism GD2 inhibitors(Disialoganglioside GD2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glioblastoma | Preclinical | South Korea | 01 Jul 2025 |





